Streck Laboratories Inc and Immunicon Corporation have amended their non-exclusive license agreement for certain Streck cell preservation technology patents. Immunicon will use Streck's technology in conjunction with Immunicon's cell isolation and analysis technology for additional types of cells.

Commenting on the agreement, Constance Ryan, President of Streck Laboratories, said: "Streck's technology offers a method to stabilize blood samples before testing. This is important for the development of reliable and accurate research and diagnostic products."

Edward L. Erickson, Chairman of the Board, President and Chief Executive Officer of Immunicon, said, "Our relationship with Streck is an important element of our overall technology strategy in the field of cellular analysis. The expansion of our license agreement will permit us to develop products in other fields of medicine and life science research, broadening the applications of our core technologies."